Rare Disease Report

Antisense Therapy and Familial Amyloid Polyneuropathy

MAY 17, 2015


Isis Pharmaceuticals is currently enrolling patients in a phase 3 study to test the safety and efficacy of the antisense drug ISIS-TTRRX in patients with Familial Amyloid Polyneuropathy.

In this interview, Merrill Benson, MD, of Indiana University discusses how the antisense drug works and why so many are interested in the results from this phase 3 study.

For more information, visit http://ttrstudy.com/attr-amyloidosis/

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
$related$
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.